The FDA has approved an immunotherapeutic in combination with chemotherapy to treat certain patients with gastric cancer, gastroesophageal junction cancer, and a common form of esophageal cancer. The U.S. Food and Drug Administration (FDA)...
Scientists discussed the mechanisms of chemotherapy-related cognitive impairment at a session dedicated to symptom science at the AACR Annual Meeting 2021.
The FDA granted accelerated approval to the targeted therapeutic sacituzumab govitecan to treat certain patients with the most common form of bladder cancer. The U.S. Food and Drug Administration (FDA) recently granted accelerated approval...
Immunotherapy has revolutionized cancer treatment over the past decade, providing potentially lifesaving therapies to many patients who otherwise would have limited options. Despite its success for many patients, immunotherapy still has challenges to overcome. Fortunately, novel strategies to improve the efficacy...
The immune systems of people with blood cancer respond differently to the coronavirus than the immune systems of people without cancer.
The launch of a campaign to address the decline in cancer screening rates, and more news of the week from Cancer Today.
A study indicates that people are delaying medical care until they are eligible for Medicare, and more news of the week from Cancer Today.
The FDA approved the first CAR T-cell therapy to treat certain adult patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) has approved idecabtagene vicleucel (Abecma) to treat adult patients with relapsed...
Underrepresentation of members of minority groups in public genomic databases could lead to misleading test results, and more news of the week from Cancer Today.
the immunotherapeutic pembrolizumab in combination with chemotherapy WAS APPROVED to treat certain adult patients with esophageal cancer. The U.S. Food and Drug Administration (FDA) recently approved the immune checkpoint inhibitor pembrolizumab (Keytruda) in combination...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More